Cellular Biomedicine Group to Release CAR-T for Non-Small Cell Lung Cancer Phase I Clinical Trial Data at 2015 European Cancer Congress

Cellular Biomedicine Group Inc. CBMG ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies for cancer, today announced a scheduled poster presentation during the 2015 European Cancer Congress (ECCO) annual meeting to be held in Vienna, Austria from September 25-29, 2015. The presentation will detail PLAGH/CBMG's Phase I clinical trial data using Chimeric Antigen Receptor-Modified T-Cells (CAR-T) targeting HER-1 for the treatment of patients with HER-1 expressing advanced relapsed/refractory Non-Small Cell Lung Cancer (NSCLC). The CAR-T trial was designed and conducted by Chinese PLA General Hospital ("PLAGH", Beijing, also known as "301 Hospital"), led by Principal Investigator Wei Dong Han, MD, PhD, head of PLAGH's cancer immunotherapy department. Dr. Han and his research team have authored several CAR-T publications, including "Tolerance and Efficacy of Autologous or Donor-derived T-Cells Expressing CD19 Chimeric Antigen Receptors in Adult B-ALL with Extramedullary Leukemia" and "Effective Response and Delayed Toxicities of Refractory Advanced Diffused Large B-cell Lymphoma Treated by CD20-directed Chimeric Antigen Receptor-modified T-cells". (OncoImmunology (Impact Factor: 6.28). 03/2015; DOI: 10.1080/2162402X.2015.1027469 and Clin Immunol. 2014 Dec;155(2):160-75. doi: 10.1016/j.clim.2014.10.002) The Company previously announced positive clinical data from its Phase I clinical trials for CD19, CD20 and CD30 constructs targeting late-stage blood cancers. Title: Chimeric Antigen Receptor-Modified T-Cells for the immunotherapy of Patients with HER-1 Expressing Advanced Relapsed/Refractory Non-Small Cell Lung Cancer Poster Session: Immunotherapy of Cancer, September 26 2015 from 16:45 to 18:45 (CEST) Abstract Number: 516 Poster Number: P250 Location: Messe Wien Exhibition & Congress Centre, Hall C Presenter: Wei Dong Han, MD, PhD, Chinese PLA General Hospital Company management will participate in the meeting and be available for discussions. Full detail of the presented data will be available on the Company website following the presentation.